Evidence map›Paper›PMID 41890713›Full record

ArticleFrontiers in immunology2026

Combining magnetic resonance imaging and evoked potentials enhances machine learning prediction of multiple sclerosis disability worsening.

Sofie Aerts, Lorin Werthen-Brabants, Hamza Khan, Diana L Giraldo, Edward De Brouwer, Lotte Geys, Veronica Popescu, Jan Sijbers, Henry C Woodruff, Tom Dhaene and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sofie Aerts *University MS Centre (UMSC), Hasselt-Pelt, Belgium.
Lorin Werthen-Brabants *IDLab, Ghent University - Imec, Ghent, Belgium.
Hamza Khan *University MS Centre (UMSC), Hasselt-Pelt, Belgium.
Diana L GiraldoImec-Vision Lab, Universiteit Antwerpen, Antwerp, Belgium.
Edward De BrouwerESAT-STADIUS, KU Leuven, Leuven, Belgium.
Lotte GeysUniversity MS Centre (UMSC), Hasselt-Pelt, Belgium.
Veronica PopescuUniversity MS Centre (UMSC), Hasselt-Pelt, Belgium.
Jan SijbersImec-Vision Lab, Universiteit Antwerpen, Antwerp, Belgium.
Henry C WoodruffThe D-Lab, Department of Precision Medicine, GROW - Research Institute for Oncology & Reproduction, Maastricht University, Maastricht, Netherlands.
Tom DhaeneIDLab, Ghent University - Imec, Ghent, Belgium.
Dirk DeschrijverIDLab, Ghent University - Imec, Ghent, Belgium.
Bart Van WijmeerschUniversity MS Centre (UMSC), Hasselt-Pelt, Belgium.
Philippe LambinThe D-Lab, Department of Precision Medicine, GROW - Research Institute for Oncology & Reproduction, Maastricht University, Maastricht, Netherlands.
Liesbet M PeetersUniversity MS Centre (UMSC), Hasselt-Pelt, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Predicting long-term disability progression in multiple sclerosis (MS) remains a significant challenge. Existing prognostic models often rely on single-modality data or conventional measures, such as lesion count on magnetic resonance imaging (MRI) or latency values from evoked potentials (EPs), overlooking subclinical disease progression. This study aimed to develop a multimodal machine learning (ML) pipeline integrating clinical, high-dimensional MRI, and motor EP time-series (EPTS) features to predict disability worsening in MS. Methods: A retrospective cohort of 127 people with MS (PwMS; 424 episodes) from a tertiary MS center in Belgium was used, including clinical data, T2-weighted fluid-attenuated inversion recovery MRI, and motor EPs. Disability worsening was defined as a change in the expanded disability status scale (EDSS) over two years, stratified by baseline EDSS. MRI features included 42 anatomical and lesion volumes and 100 radiomic descriptors from lesions and the normal-appearing white matter (NAWM). EPTS features included latency, peak-to-peak amplitude (PPA), and high-dimensional descriptors selected using highly comparative time-series analysis (HCTSA) and Boruta. ML models (Light Gradient Boosting Machine (LGBM), random forest, logistic regression) were trained using 20×repeated stratified 3-fold cross-validation. Performance was evaluated using the area under the receiver operating characteristic curve (AUROC), average precision (AP), and Brier score. SHapley Additive exPlanations (SHAP) were used for interpretability. Results: Across 96 model configurations, models combining MRI and EPTS features, with or without clinical data, consistently outperformed single-modality models across AUROC, AP, and Brier score, regardless of algorithm or feature representation. The best-performing model (Brier score = 0.062) was an LGBM using combined MRI and EPTS data. MRI radiomics dominated feature importance, especially shape- and texture-based features from NAWM and lesion regions. EPTS features, particularly waveform dynamics (e.g., Sliding Window) and PPA, provided complementary value and improved sensitivity. EPTS-only models showed the highest AUROC, but combined models achieved the best overall balance across all performance metrics. Conclusion: This is the first study to integrate clinical, MRI radiomics, and motor EPTS features in an ML pipeline for MS prognosis. Combining structural and functional subclinical markers improves the prediction of disability worsening and supports multimodal monitoring for personalized care.

Indexed as

Evoked PotentialsMachine LearningMagnetic Resonance ImagingMultiple SclerosisAdultBoosting Machine Learning AlgorithmsDisability EvaluationDisease ProgressionFemaleHumansMaleMiddle AgedPrediction AlgorithmsPredictive Learning ModelsPrognosisRadiomicsdisease worseningevoked potentialsmachine learningmagnetic resonance imagingmultiple sclerosisprognosisradiomics

Identifiers

PMID41890713
PMCPMC13013075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.